Novartis and Alnylam recently collaborated to leverage proprietary siRNA technology to develop liver-targeted therapy as an alternative to transplantation for patients experiencing liver...
Johnson & Johnson recently announced that its COVID-19 vaccine, Ad26.COV2.S, was 85 percent effective against coronavirus-related hospitalization in a Phase 3b study.
The South African Medical...
Hackensack Meridian Health recently announced its support of the clinical development of a highly-differentiated immuno-oncology platform from Alloplex Biotherapeutics.
This investment is...
Pfizer and BioNTech recently announced that they will amend the clinical study evaluating the safety, tolerability, and immunogenicity of their COVID-19 vaccine in children.
The Phase 1/2/3 trial...
FDA recently approved ViiV Healthcare’s long-acting injectable pre-exposure prophylaxis (PrEP) treatment, Apretude, to reduce the risk of sexually acquired HIV-1.
The agency approved Apretude...
Bristol Myers Squibb and clinical-stage biopharmaceutical company Immatics recently entered into a license, development, and commercialization agreement for the bispecific T-cell candidate,...
Johnson & Johnson recently announced preliminary results from an independent study, which showed that a booster shot of its COVID-19 vaccine increased both antibody and T-cell responses.
In the...
Roche and TIB Molbiol recently added three additional research use only test kits to detect mutations present in the Omicron COVID-19 variant.
The three test kits, VirSNip SARS Spike ins214EPE,...
Johnson & Johnson recently announced that it will evaluate its COVID-19 vaccine against the new and rapidly spreading Omicron variant.
Specifically, Johnson & Johnson is testing blood...
GSK recently appointed Phil Dormitzer, MD, PhD, as global head of vaccines research and development and a member of the vaccines leadership team.
Previously, Dormitzer was vice president and chief...
Pfizer and BioNTech recently announced that their COVID-19 vaccine, BNT162b2, was 100 percent effective in adolescents 12 through 15 years of age in a longer-term analysis.
Researchers also...
Eli Lilly and Company recently announced that Jardiance slowed kidney function decline in adults with heart failure with left ventricular ejection fraction (LVEF) over 40 percent regardless of chronic...
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recently recommended the approval of Roche’s COVID-19 antibody combination, Ronapreve.
CHMP...
GSK recently announced that its drug, daprodustat, was safe and effective in patients with anemia due to chronic kidney disease (CKD).
The Phase 3 ASCENT trial studied the hypoxia-inducible...
Moderna and Metagenomi recently entered into a strategic research and development collaboration to advance new gene editing systems for in vivo human therapeutic applications.
Under the terms of the...
Gilead and Merck recently announced the start of a Phase 2 clinical study evaluating a combination HIV treatment regimen in adults living with the disease.
The open-label study will evaluate the...
Pfizer recently announced that its COVID-19 treatment, PAXLOVID, reduced hospitalization and death in high-risk adults with coronavirus by 89 percent compared to placebo.
In the Phase 2/3...
The CDC Advisory Committee on Immunization Practices (ACIP) recently recommended Pfizer and BioNTech’s pediatric COVID-19 vaccine for children five to 11 years of age.
The organization now...
The National Institutes of Health (NIH), FDA, ten pharmaceutical companies, and five non-profit organizations recently partnered to boost the development of gene therapies for 30 million Americans...
